Insider Buying: GSK plc (LON:GSK) Insider Acquires 446 Shares of Stock

GSK plc (LON:GSK) insider Elizabeth (Liz) McKee Anderson bought 446 shares of the stock in a transaction on Monday, September 23rd. The shares were acquired at an average cost of GBX 2,051 ($27.46) per share, for a total transaction of £9,147.46 ($12,248.88).

GSK Stock Down 0.3 %

GSK stock opened at GBX 1,522 ($20.38) on Friday. The firm has a market cap of £62.10 billion, a PE ratio of 1,346.90, a PEG ratio of 1.34 and a beta of 0.31. GSK plc has a 1 year low of GBX 1,371.40 ($18.36) and a 1 year high of GBX 1,823.50 ($24.42). The company has a fifty day simple moving average of GBX 1,584.23 and a 200 day simple moving average of GBX 1,628.78. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04.

GSK Dividend Announcement

The business also recently declared a dividend, which will be paid on Thursday, October 10th. Shareholders of record on Thursday, August 15th will be given a GBX 15 ($0.20) dividend. The ex-dividend date is Thursday, August 15th. This represents a dividend yield of 0.97%. GSK’s dividend payout ratio is currently 5,309.73%.

Analysts Set New Price Targets

GSK has been the subject of several research reports. Jefferies Financial Group restated a “buy” rating and set a GBX 2,100 ($28.12) price target on shares of GSK in a report on Thursday, June 27th. Citigroup decreased their target price on shares of GSK from GBX 2,120 ($28.39) to GBX 1,900 ($25.44) and set a “buy” rating for the company in a research note on Friday, July 5th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 1,820 ($24.37) price target on shares of GSK in a research note on Tuesday, September 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,850 ($24.77) price objective on shares of GSK in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,842.50 ($24.67).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.